Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 97 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2014', provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 9
Therapeutics Development 10
Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 10
Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis 11
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 12
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 17
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 19
AbbVie Inc. 19
Amarantus Bioscience Holdings, Inc. 20
Avineuro Pharmaceuticals, Inc. 21
BIOPROJET SCR 22
CoMentis, Inc. 23
Eli Lilly and Company 24
FORUM Pharmaceuticals Inc. 25
H. Lundbeck A/S 26
Intra-Cellular Therapies, Inc. 27
Iproteos S.L. 28
Merck & Co., Inc. 29
Mithridion, Inc. 30
Mnemosyne Pharmaceuticals, Inc. 31
Novartis AG 32
Pfizer Inc. 33
Saniona AB 34
Siena Biotech S.p.A. 35
SK Biopharmaceuticals Co., Ltd. 36
Takeda Pharmaceutical Company Limited 37
Upsher-Smith Laboratories, Inc. 38
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
A-431404 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ABT-126 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AN-761 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AQW-051 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AUT-1 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AVL-3288 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AVN-211 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BNC-375 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CDD-0304 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
eltoprazine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
encenicline hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
erteberel - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GTS-21 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
IPR-001 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IPR-088 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ITI-214 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
LUAF-64280 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PNU-120596 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
roflumilast - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SEN-15924 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SKL-15508 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Agonize NMDA2B for CIAS - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TAK-058 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
tiprolisant - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Cognitive Impairment Associated With Schizophrenia (CIAS) - Recent Pipeline Updates 83
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects 92
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products 94
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones 95
Featured News & Press Releases 95
Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 95
Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

List of Tables
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2014 10
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Development by Companies, H2 2014 (Contd..1) 18
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H2 2014 19
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 20
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2014 21
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by BIOPROJET SCR, H2 2014 22
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by CoMentis, Inc., H2 2014 23
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H2 2014 24
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 25
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H2 2014 26
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 27
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H2 2014 28
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Merck & Co., Inc., H2 2014 29
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mithridion, Inc., H2 2014 30
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 31
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Novartis AG, H2 2014 32
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H2 2014 33
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H2 2014 34
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Siena Biotech S.p.A., H2 2014 35
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 36
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 37
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 38
Assessment by Monotherapy Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 43
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 47
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Recent Pipeline Updates, H2 2014 83
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2014 92
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H2 2014 93
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2014 94